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ARTICLE
A pathway-centric approach to rare variant association
analysis
Tom G Richardson1, Nicholas J Timpson1, Colin Campbell2 and Tom R Gaunt*,1
Current endeavours in rare variant analysis are typically underpowered when investigating association signals from individual
genes. We undertook an approach to rare variant analysis which utilises biological pathway information to analyse functionally
relevant genes together. Conventional ﬁltering approaches for rare variant analysis are based on variant consequence and are
therefore conﬁned to coding regions of the genome. Therefore, we undertook a novel approach to this process by obtaining
functional annotations from the Combined Annotation Dependent Depletion (CADD) tool, which allowed potentially deleterious
variants from intronic regions of genes to be incorporated into analyses. This work was undertaken using whole-genome
sequencing data from the UK10K project. Rare variants from the KEGG pathway for arginine and proline metabolism were
collectively associated with systolic blood pressure (P=3.32x10−5) based on analyses using the optimal sequence kernel
association test. Variants along this pathway also showed evidence of replication using imputed data from the Avon Longitudinal
Study of Parents and Children cohort (P=0.02). Subsequent analyses found that the strength of evidence diminished when
analysing genes in this pathway individually, suggesting that they would have been overlooked in a conventional gene-based
analysis. Future studies that adopt similar approaches to investigate polygenic effects should yield value in better understanding
the genetic architecture of complex disease.
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INTRODUCTION
Genome-wide association studies (GWAS) have been successful in
identifying novel susceptibility loci across a range of complex
diseases. However, the underlying mechanisms by which associated
variants inﬂuence disease or quantitative phenotypes are often
undeﬁned and the variance that they explain is almost always small.
Next-generation sequencing (NGS) has allowed rarer genetic
variants (that is, minor allele frequency (MAF)o1%), which may
potentially contribute substantively to phenotypic variance,1–4 to be
genotyped and imputed in larger samples than before. The analysis
of these variants, potentially with larger effect sizes,1 may prove
vital in understanding this missing heritability and uncovering the
genetic architecture of complex disease.
Study designs over the last decade have largely concerned the
genetic contribution of common variants and thus lack power when
applied to rare variants. In order to improve power when analysing
these variants using NGS data, methodology based on their aggrega-
tion has been developed. Some of these techniques are based on
dispersion (c-alpha,5 SKAT6) and are more robust when analysing rare
variants that have conﬂicting directions of effect for a phenotype of
interest (protective or deleterious). Despite this, rare variant analyses
remain underpowered, owing to inadequate samples sizes and the
manner in which the genome is partitioned. One way in which
statistical power can potentially be increased is by analysing combina-
tions of variants which have a similar functional impact from within
genes that lie along the same molecular pathway.
Such an alternative approach is attractive for several reasons,
including a reduction on the burden for multiple testing and
identiﬁcation of association signals contributed to by multiple
genes, which would have otherwise been overlooked using single
gene approaches. Expanding the region of interest to collapse
variants together across multiple genes also has its challenges, such
as choice of pathway deﬁnitions. Clearly, aggregating variants
together from genes which are not functionally relevant will hinder
analyses rather than enrich them. Several studies have already
attempted to analyse NGS data with pathway or gene network-
based approaches, although generally their ﬁndings have been
underwhelming.7–9 However, the prospect for developing an
approach that successfully identiﬁes polygenic effects from rare
variants is potentially very rewarding.
This study aimed to undertake a novel approach to rare
variant analysis by focusing on their aggregation across predicted
biological pathways, rather than individual loci. Hypothetically,
analysing variants from within collective regions may provide
stronger evidence of association with phenotypic outcome than
single gene approaches. Furthermore, we wanted ﬁndings to allow
biologically meaningful inferences to be made with regards to the
mechanisms of complex disease, which would not be possible
when analysing individual genes in isolation. Follow-up analyses of
signals detected at a pathway level were performed in order to
isolate the evidence of association back to individual genes
and variants. We undertook this analysis using whole-genome
sequencing (WGS) from participants involved in the UK10K
project and cardiovascular phenotypes as measured in the Avon
Longitudinal Study of Parents and Children (ALSPAC)10 and
TwinsUK11 cohorts.
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MATERIALS AND METHODS
Cohort description
The UK10K consortium has two main project arms. In this study, we have used
data from the cohorts’ arm, which was designed to investigate the contribution
of genome-wide genetic variation to a range of quantitative traits. This arm
contains individuals from two intensively studied cohorts of European ancestry,
ALSPAC and TwinsUK:
ALSPAC. ALSPAC is a population-based cohort study investigating genetic
and environmental factors that affect the health and development of children.
The study methods are described in detail elsewhere10,12 (http://www.bristol.ac.
uk/alspac).
Ethical approval was obtained from the National Research Ethics Service
(NRES) Committee, South East London, REC 2. Written informed consent was
obtained from parents for all measurements made.
TwinsUK. The TwinsUK registry is a cohort of volunteer adult twins from all
over the United Kingdom.11 Initially, only middle-aged women were recruited
and as a result 83% of the registry is female. The registry currently contains
51% monozygotic and 49% dizygotic twins aged 18–103 years. Further details
are available online (http://www.twinsuk.ac.uk/).
Informed consent was obtained from participants before they entered the
study and ethical approval was granted by the NRES Committee, Westminster,
London.
Sequencing data
DNA Samples from 4030 UK10K study participants (2040 offspring from the
ALSPAC cohort, 1990 from the TwinsUK cohort) were subjected to low
coverage (6–8× average read depth) WGS. Sequencing was performed at both
the WTSI and the Beijing Genomics Institute (BGI). DNA (1–3 μg) was sheared
to 100–1000 bp using a Covaris E210 or LE220 (Covaris, Woburn, MA, USA).
Sheared DNA was size subjected to Illumina paired-end DNA library
preparation. Following size selection (300–500 bp insert size), DNA libraries
were sequenced using the Illumina HiSeq platform as paired-end 100 base reads
according to manufacturer’s protocol.
Data that passed quality control (QC) was aligned to the GRCh37 human
reference used in phase 1 of the 1000 Genomes Project. Reads were
aligned using BWA (v0.5.9-r16).13 Of the 4030 participants, 3910 samples
(1976 ALSPAC and 1934 TwinsUK) went through the variant calling
procedure. Low-quality samples were identiﬁed by comparing the samples to
their GWAS genotypes using ~ 20 000 sites on chromosome 20. A total of 112
samples (48 ALSPAC and 64 TwinsUK) were removed, leaving 3798 samples
(1928 ALSPAC and 1870 TwinsUK) that were eligible for the genotype
reﬁnement phase.
Missing and low-conﬁdence genotypes in the ﬁltered VCFs were reﬁned out
using the imputation procedure in BEAGLE 414 with default parameters.
Additional sample-level QC steps were carried out on reﬁned genotypes,
resulting in 17 samples (16 TwinsUK and 1 ALSPAC) being removed owing to
either non-reference discordance with GWAS SNV data45%, multiple
relations to other samples or failed sex check. A principal components analysis
was conducted using EIGENSTRAT15 to exclude participants of non-European
ancestry after merging our data with a pruned 11 HapMap3 population data
set.16 Forty-four subjects (12 TwinsUK and 32 ALSPAC) did not cluster to the
European cluster and were removed. The ﬁnal sample size for association
analyses comprised of 3621 individuals (1754 TwinsUK and 1867 ALSPAC).
UK10K phenotypes
ALSPAC. Body mass index (BMI), systolic blood pressure (SBP), diastolic
blood pressure (DBP) and non-fasting blood samples were obtained from the
age 9 clinic (mean age: 9.9, range: 8.9–11.5). The blood samples were used to
determine lipids including total cholesterol (TC), triglycerides (TG) and high-
density lipoproteins (HDL) using a modiﬁcation of the standard Lipid Research
Clinic Protocol.17 Low-density lipoproteins were subsequently calculated using
the Friedwald equation:18
TwinsUK. BMI, SBP, DBP and blood samples taken after at least 6 h of
fasting were obtained from study participants (mean age: 56, range: 17–85).
A colorimetric enzymatic method was used to determine TC, TG and HDL-c
levels. The Friedewald equation was used to calculate LDL-c levels in subjects.
Further details on phenotype measurements in the UK10K consortium are
provided in the Supplementary Material (Supplementary Information 1).
ALSPAC imputed data for replication analyses
Genome-wide association (GWA) data was also available for 6557 ALSPAC
samples who were not enroled in the UK10K project. This data was
genotyped using the Illumina HumanHap550 quad genome-wide SNP
genotyping platform (Illumina Inc, San Diego, CA, USA) by the Wellcome
Trust Sanger Institute (WTSI, Cambridge, UK) and the Laboratory Corporation
of America (LCA, Burlington, NC, USA). All individuals passed QC based on
incorrect sex assignment; abnormal heterozygosity (o0.320 or 40.345 for
WTSI data; o0.310 or 40.330 for LCA data); high missingness (43%);
cryptic relatedness (410% identity by descent) and non-European ancestry
(detected by multidimensional scaling analysis).
Variants discovered through WGS in the UK10K project were used for the
development and use of a reference panel for this imputation within the
ALSPAC and TwinsUK GWA data sets. These were combined with known
variants taken from the 1000 Genomes reference panel. Novel functionality was
developed in IMPUTE219,20 to use each reference panel to impute missing
variants in their counterparts before ultimately combining them together. This
meant that all loci involved in the discovery analysis were imputed in this
sample. Further detail on this imputation process can be found in the
publication by Timpson et al.20 All rare variants (MAF≤ 1%) were ﬁltered to
have Hardy–Weinberg equilibrium P45× 10− 7. As accurate imputation of rare
variants can be challenging, only variants with an imputation quality score of
0.4 or higher were used in this analysis. Phenotype measurements were
collected as before for lipid traits, although for BMI, SBP and DBP we used
measurements obtained from the focus at age 7 clinic (mean age: 7.5, range:
7.1–8.8) in order to maximise sample size.
Please note that the study website contains details of all the data that are
available through a fully searchable data dictionary (http://www.bris.ac.uk/
alspac/researchers/data-access/data-dictionary). Ethical approval was obtained
from the ALSPAC Law and Ethics Committee and the Southmead, Frenchay,
UBHT and Weston Research Ethics Committees. Written informed consent
was obtained from parents for all measurements made.
Statistical analysis
BioCarta, KEGG and Reactome pathways analyses with cardiovascular traits.
Pathway deﬁnitions were obtained from three pathway databases (BioCarta,21
KEGG22 and Reactome23). This was achieved by downloading gene sets from
the Broad institute’s molecular signatures database (MSigDB, found at http://
www.broadinstitute.org/gsea/downloads.jsp) which is used by the GSEA
algorithm.24 All rare genetic variants (MAF≤ 1%) that survived QC were
aggregated together across pathways according to UCSC reference genome hg19
deﬁnitions. We then ﬁltered these sets to only include nonsynonymous variants
according to the Ensembl Variant Effect Predictor (VEP).25 This process was
repeated for a separate analysis except using variants resulting in a loss-of-
function (that is, stop gains/losses, splice sites or frameshift indels according to
VEP annotations). In a ﬁnal set of analyses, we used the Combined Annotation
Dependent Depletion (CADD)26 resource to ﬁlter variants based on
molecular functionality and pathogenicity. Based on simulations using network
analyses surrounding candidate loci (Supplementary Information 2 and
Supplementary Figure 1), we hypothesised that a strict threshold would be
necessary for this analysis and therefore only included the top 1% most
deleterious variants in the UK10K WGS data as predicted by CADD (that is, all
variants with a CADD C-Score ≥ 20).
Rare variants (MAF≤ 1%) from these regions were then analysed with
each cardiovascular trait using the optimal sequence kernel association test
(SKAT-O).27 Adjustment for the ﬁrst 10 ancestry principal components was
undertaken for all analyses as it has been reported that only adjusting for a
small number of top principal components when analysing rare variants can
lead to inﬂated type 1 error rates.28 Screeplots suggested that this should be
sufﬁcient to account for any potential population stratiﬁcation in the planned
analyses (Supplementary Figure 2).
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Multiple comparisons and permutation testing. Results that survived the
conservative multiple testing threshold (0.05/# of pathways analysed) were
further evaluated by performing 100 000 permutation tests. For each test, the
same set of genotype values was reanalysed as before except after randomly
shufﬂing phenotype values among individuals. P-values were evaluated as
robust to permutation if no more than 10 permuted P-values were smaller than
the P-values observed when phenotypes were not shufﬂed (that is, the observed
association).
Follow-up analyses to isolate association signals. We followed up pathways that
were robust to permutation testing by analysing all genes individually across the
genome using the appropriate variant ﬁltering technique and corresponding
phenotype. Results were plotted using Manhattan plots, highlighting genes
located along the pathway of interest.
We also examined protein–protein interactions to elucidate subnetworks of
genes within any pathways with strong evidence of association in the previous
analysis. These subnetworks were determined due to the most connected genes
in the pathway based on STRINGdb experimental data. Circos plots29 were
used to visualise how these subnetworks interacted across the genome.
Subnetworks of genes were analysed in a similar manner to before in order
to isolate association signals across pathways.
Replication. Using the imputed ALSPAC data set, we attempted to replicate
evidence of association for pathways that survived the multiple testing threshold
and were robust to permutation testing. All SNVs in pathways found to be
associated in the UK10K data (with imputation quality≥ 0.4) were collapsed
together as before and SKAT-O analyses were repeated using the respective
trait. SNVs with an imputation quality score less than this were not included in
this analysis. All SNVs in this analysis were also collapsed according to
individual gene coordinates to see if there was any overlap with key genes
identiﬁed in the discovery analysis. As before, analyses were adjusted for the top
10 principal components. Single variant analyses were also undertaken using
PLINKv1.930 to verify whether there were any key SNVs in both sets of
analyses. All other statistical analyses in this study were undertaken using R
statistical software.31
RESULTS
Figure 1 shows a ﬂowchart of the planned analysis for this study.
In total, 3621 individuals with WGS data from the UK10K cohort
were available for analysis. After merging individuals with each
cardiovascular trait that we planned to analyse, ﬁnal sample sizes
ranged between 3538 and 3191 (3538 for BMI, 3309 for SBP and DBP,
3210 for HDL, 3191 for LDL, 3206 for TC and 3202 for TG).
KEGG, Reactome and BioCarta pathways analyses with
cardiovascular traits
In total, 1095 pathway deﬁnitions were obtained from the three
pathway databases. We observed no strong evidence of association for
any pathway results after ﬁltering to only include nonsynonymous
variants based on the multiple testing correction threshold
(0.05/1095=Po4.57×10− 5). Results can be located in Supplementary
Table 1. There were four results that survived the multiple
testing correction threshold in the loss-of-function analysis with TG
(0.05/897=Po5.57× 10− 5). However, all these signals were driven by
a single rare variant located within the APOC3 gene region
(rs138326449), which has been previously identiﬁed in the UK10K
data set.20 These results can be located in Supplementary Table 2.
The following results for our study now solely concern the analysis
based on ﬁltering variants based on their CADD score. One pathway
result survived the conservative correction for multiple testing
(Po4.65× 10− 5, that is, 0.05/1.075 based on the number of pathways
with two or more rare variants after ﬁltering by a CADD C-Score
threshold of ≥ 20), which was associated with SBP. This was the
Figure 1 A ﬂowchart illustrating the pipeline for analysis in this study. CADD, combined annotation dependent depletion tool; SKAT-O, optimal sequence
kernel association tool; ALSPAC, avon longitudinal study of parents and children.
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KEGG arginine and proline Metabolism pathway (P= 3.32× 10− 5),
referred to hereafter as the arginine and proline pathway. The top
results from this analysis can be located in Table 1. The strongest
evidence of association in the BMI analysis was with variants along the
IGF1 pathway according to BioCarta, although this did not survive the
threshold for multiple testing (P= 2.88× 10− 4). The top results
for this analysis and all other traits can be found in Supplementary
Tables 3.
Permutation testing
No permuted P-value survived the multiple testing threshold based on
the 100 000 iterations undertaken. Furthermore, only three permuted
P-values were lower than the observed association between the
arginine and proline pathway and SBP (Supplementary Table 4).
These results supported evidence that this effect was not due to
chance.
Follow-up analyses to isolate association signals
We collapsed all rare variants (MAF≤ 1%) across the genome with a
CADD C-Score threshold of ≥ 20 within individual gene regions
according to coordinates based on UCSC reference genome hg19
deﬁnitions. Each gene-based set of variants was analysed using
SKAT-O with SBP. Figure 2 shows a Manhattan plot for the results
of this analysis. Genes located along the arginine and proline pathway
are highlighted. Notably, none of these P-values survived the threshold
for multiple comparisons (Po6.05× 10− 6 (0.05/8269, based on the
8269 gene regions with two or more variants analysed)). This shows
that a conventional gene-based approach would not have been able to
detect the effect across rare variants in the arginine and proline
pathway. Supplementary Table 5 show the results for this individual
gene analysis for genes located on this pathway.
We also examined protein–protein interactions according to
Stringdb32 experimental data to identify subnetworks of genes within
the arginine and proline pathway. There were three genes within this
pathway (CPS1, PRODH2 and GLUD1), which had more interactions
than any others and therefore subnetworks were based around all
genes directly connected to them. Figure 3 displays a Circos plot,29
which illustrates interactions between subnetworks within this
pathway. Variants within these subnetworks were analysed as before
using SKAT-O with SBP. Two subnetworks (the CPS1 and GLUD1
subnetworks) provided stronger evidence of association over any
individual gene analysis (P= 1.58× 10− 4 and 1.30× 10− 3, respec-
tively), however only when all genes in the network were analysed
together did evidence become strong enough to survive the threshold
for multiple testing in the initial analysis (P= 4.65× 10− 5). Table 2
shows the full results of this analysis.
Replication using ALSPAC imputed data
We undertook a replication analysis using imputed data from the
ALSPAC data set using individuals who were not enroled in the
UK10K project (that is, data from a completely separate population of
individuals than those already analysed). We replicated evidence of
association in the imputed data set between variants along the arginine
and proline pathway and SBP (P= 0.02 from 71 variants, N= 4380).
Evidence of association appeared to be consistent from both the
discovery and replication analyses for variants within the NOS1 gene
(P= 0.06 and P= 0.05, respectively), although there was little con-
cordance between key individual variant results between the discovery
and replication sets of analyses (Supplementary Tables 6–8).
Table 1 Systolic blood pressure results using a minor allele frequency cutoff of 1%
Pathway Variantsa UK10K P-value TwinsUK P-value ALSPAC P-value
KEGG: arginine and proline metabolism 115 3.32×10−5 7.42×10−4 0.04
Reactome: amino acid synthesis and interconversion transamination 26 9.69 ×10−4 0.04 0.06
KEGG: antigen processing and presentation 18 5.78 ×10−3 0.27 0.02
Reactome: synthesis secretion and deacylation of ghrelin 13 6.12 ×10−3 0.04 0.13
KEGG: tight junction 412 8.48×10−3 0.29 0.36
KEGG: Jak Stat signalling pathway 90 0.01 0.34 0.04
BioCarta: cytokine pathway 5 0.01 1.91×10−3 0.48
Reactome: regulation of IFNG signalling 20 0.01 0.38 0.02
Reactome: assembly of the pre replicative comple× 97 0.02 0.12 0.12
BioCarta: RAB pathway 9 0.02 0.15 0.05
aVariants=number of variants, UK10K P-value=SKAT-O P-value for entire UK10K sample, Twins P-value, SKAT-O P-value for only TwinsUK individuals, ALSPAC P-value=SKAT-O P-value for only
ALSPAC individuals.
Figure 2 A Manhattan plot illustrating gene-based collapsing of rare variants
(MAF≤1%) genome-wide using SKAT-O with systolic blood pressure.
Red annotated points represent genes which reside along the arginine and
proline pathway.
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DISCUSSION
We present an approach to rare variant analysis that expands the
region of interest from individual genes to established biological
pathways. This approach uses a variant ﬁltering method that incorpo-
rates functional annotations from the CADD tool, which allows both
intronic and exonic variants to be included into analyses. This is in
contrast to conventional ﬁltering methods in rare variant analysis,
which are based on variant consequence and are therefore conﬁned to
coding regions. Implementing this approach has identiﬁed evidence to
suggest a set of functionally relevant rare variants collectively inﬂuence
SBP. Evaluations of this pathway identiﬁed subsets of genes that were
predominantly responsible for the observed signal, although only
when analysed as an entire pathway did statistical evidence become
robust enough to survive the correction for multiple comparisons.
The observed association between genes involved in the metabolism
of arginine and proline and SBP (P= 3.32× 10− 5 from 115 variants,
Figure 3 Circos plot representing the genomic location of Genes in the Arginine and Proline pathway and how their protein products interact according to
Stringdb. Stringdb suggested that the protein products of three genes along the Arginine and Proline pathway had the most interactions based on
experimental evidence. The following three subnetworks are based on the interactions for each of these genes (CPS1, PRODH2 and GLUD1): CPS1, NOS1,
NOS2, NOS3, ALDH9A1, ARG2, ALDH18A1, ALDH1B1, ALDH2, ALDH7A1, ALDH4A1, GOT1 and GOT2. PRODH2, NOS1, NOS2, NOS3, PYCR1,
ALDH9A1, ALDH4A1, ALDH2, ALDH7A1 and ALDH1B1. GLUD1, CKM, CKMT2, CKB, ALDH1B1, ALDH7A1, ALDH2, ALDH9A1, ALDH4A1 and GOT2.
Red, blue and purple links are used to differentiate the three subnetworks.
Table 2 Subnetwork analysis for the KEGG arginine and proline metabolism pathway with systolic blood pressure
UK10K TwinsUK ALSPAC
Genes in Subnetwork Variantsa P-value Variantsa P-value Variantsa P-value
CPS1, NOS1, NOS2, NOS3, ALDH9A1, ARG2, ALDH18A1, ALDH1B1, ALDH2, ALDH7A1,
ALDH4A1, GOT1 and GOT2
57 1.58×10−4 38 4.00×10−3 40 0.03
PRODH2, NOS1, NOS2, NOS3, PYCR1, ALDH9A1, ALDH4A1, ALDH2, ALDH7A1 and ALDH1B1 25 0.02 18 0.16 20 0.15
GLUD1, CKM, CKMT2, CKB, ALDH1B1, ALDH7A1, ALDH2, ALDH9A1, ALDH4A1 and GOT2 34 1.30×10−3 25 0.02 26 0.06
aVariants=number of variants analysed, UK10K= all individuals within UK10K project, TwinsUK= only TwinsUK partition of the UK10K project, ALSPAC= only ALSPAC partition of the UK10K
project, P-value=P-values according to SKAT-O test.
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N= 3309) in the UK10K data set appeared to replicate in the imputed
ALSPAC data set (P= 0.02 from 71 variants, N= 4380). There is
evidence to suggest that both these amino acids can inﬂuence blood
pressure, although arginine in particular has gained interest with
several studies reporting a blood pressure lowering effect due to
arginine dietary supplements.33–35 An important function of arginine
is a necessary precursor for the synthesis of nitric oxide, where the
impairment of nitric oxide bioavailability has been shown to be a risk
factor for hypertension.36 NOS1 was observed to be one of the key
genes in both the discovery and replication analyses within this study.
This gene belongs to the family of nitric oxide synthases and is
involved in the synthesis of nitric oxide from arginine, making it an
interesting candidate to explore the mechanisms within this pathway
and its effect on blood pressure.
We observed a lack of concordance between key individual variants
in the discovery and replication analyses, although this can most likely
be explained by the typically observed lack of power when conducting
single variant analyses on rare variants.37,38 Replication in another
cohort was also contemplated but not undertaken owing to the
challenge of identifying a cohort where a sufﬁcient proportion of
variants within the discovery analysis were genotyped. Moreover,
variants at this frequency are more likely to be population speciﬁc in
comparison with replication for GWAS hits, which makes replication
of rare variant signals challenging, particularly in a trans-ethnic
context.39 An attractive alternative therefore to the manner in which
rare variants have been analysed in this study is to meta-analyse results
using software such as RAREMETAL.40
As larger sample sizes and lower coverage for sequence data become
available this approach should also provide a powerful approach to
uncover the role of extremely rare genetic variants (MAF≤ 0.5%). For
future applications of this approach we advise implementing a strict
variant ﬁltering phase before analysis in order to remove as much
statistical noise as possible. In our initial analysis when ﬁltering
variants by conventional methods based on variant consequence we
did not observe any novel evidence of association in the UK10K data
set. However, when incorporating annotations from CADD we were
able to identify a previously undetected signal. Although other studies
have incorporated non-coding annotations into their analyses to great
effect,41 this study presents an approach for utilising them in the
context of rare variant analysis within a pathway-centric framework.
This is a noteworthy point as when performing a conventional gene-
based analysis evidence of association for this novel signal diminished.
The limitation of this approach is that potential causal variants may
be ﬁltered out when based on CADD predictions. In this study we
have chosen pathway deﬁnitions using the KEGG, Reactome and
BioCarta resources, although future studies may beneﬁt from incor-
porating gene sets based on alternative deﬁnitions. We have also
showcased SKAT-O as an adaptive method suited to this approach.
Along with its capability to identify phenotype associated regions of
variation, which can have conﬂicting directions of effect, the manner
in which SKAT-O adjusts for LD, using the Davies method,42 also
makes it an attractive approach when analysing multiple genes in a
pathway which can potentially have close proximity. As reported by
other studies, analysing pathway sets of variants using SKAT-O, or
with any other collapsing method, remains relatively underpowered.7,8
Power calculations from the replication analysis in this study also
support this, as evaluations found observed power to diminish as the
sample size and percentage of variants in the sample were reduced
(Supplementary Information 3).
Success from rare variant association analyses has been limited thus
far.43,44 In recent years, studies have attempted to improve statistical
power in their approaches by increasing their sample sizes,45 adapting
current methodological techniques46 or conducting analyses on
remote or isolated populations where the allele frequency of rarer
variants may be heightened.47 By expanding our deﬁnition of a
biologically functional unit from individual genes, we have provided
an alternative method to leverage statistical power. Furthermore,
subsequent analysis concerning pathway enrichment (for example,
GSEA24) would struggle to detect an over representation of genes
along certain pathways. Our approach allows pathological mechanistic
insights to be made which methods involving individual gene regions
would not. This is also an advantage over individual variant methods,
such as GWAS, where the majority of robustly associated ﬁndings lie
in non-coding regions, leaving questions regarding the variants’
functional impact.48 As larger samples of low coverage sequence data
become available, future studies should beneﬁt from using this
approach to uncover the genetic architecture of complex traits that
contribute to disease.
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